218 related articles for article (PubMed ID: 29196709)
21. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
McCaig AM; Cosimo E; Leach MT; Michie AM
Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
[TBL] [Abstract][Full Text] [Related]
22. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
23. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2012; 2012():88-96. PubMed ID: 23233565
[TBL] [Abstract][Full Text] [Related]
24. Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors.
Kofler DM; Büning H; Mayr C; Bund D; Baumert J; Hallek M; Wendtner CM
Gene Ther; 2004 Sep; 11(18):1416-24. PubMed ID: 15269708
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
26. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
27. SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2.
von Wenserski L; Schultheiß C; Bolz S; Schliffke S; Simnica D; Willscher E; Gerull H; Wolters-Eisfeld G; Riecken K; Fehse B; Altfeld M; Nollau P; Binder M
Leukemia; 2021 Apr; 35(4):1073-1086. PubMed ID: 32826957
[TBL] [Abstract][Full Text] [Related]
28. [Targeted treatment of chronic lymphocytic leukaemia].
Niemann CU
Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.
Huber S; Oelsner M; Decker T; zum Büschenfelde CM; Wagner M; Lutzny G; Kuhnt T; Schmidt B; Oostendorp RA; Peschel C; Ringshausen I
Leukemia; 2011 May; 25(5):838-47. PubMed ID: 21293487
[TBL] [Abstract][Full Text] [Related]
30. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
[TBL] [Abstract][Full Text] [Related]
31. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
[TBL] [Abstract][Full Text] [Related]
32. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
[TBL] [Abstract][Full Text] [Related]
33. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Chen L; Widhopf G; Huynh L; Rassenti L; Rai KR; Weiss A; Kipps TJ
Blood; 2002 Dec; 100(13):4609-14. PubMed ID: 12393534
[TBL] [Abstract][Full Text] [Related]
34. Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
McKenna MK; Noothi SK; Alhakeem SS; Oben KZ; Greene JT; Mani R; Perry KL; Collard JP; Rivas JR; Hildebrandt GC; Fleischman RA; Durbin EB; Byrd JC; Wang C; Muthusamy N; Rangnekar VM; Bondada S
Blood; 2018 Jun; 131(26):2943-2954. PubMed ID: 29695515
[TBL] [Abstract][Full Text] [Related]
35. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
36. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
Chen R; Tsai J; Thompson PA; Chen Y; Xiong P; Liu C; Burrows F; Sivina M; Burger JA; Keating MJ; Wierda WG; Plunkett W
Blood Cancer J; 2021 Mar; 11(3):57. PubMed ID: 33714981
[TBL] [Abstract][Full Text] [Related]
37. Regulation of BCR signal transduction in B-1 cells requires the expression of the Src family kinase Lck.
Dal Porto JM; Burke K; Cambier JC
Immunity; 2004 Sep; 21(3):443-53. PubMed ID: 15357954
[TBL] [Abstract][Full Text] [Related]
38. B cell receptor signaling in chronic lymphocytic leukemia.
Burger JA; Chiorazzi N
Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
[TBL] [Abstract][Full Text] [Related]
39. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
40. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Ten Hacken E; Burger JA
Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
